LUCIUS 卢修斯 瑞普替尼 Repotrectinib非小细胞肺癌

瑞普替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品
老挝国家食药监局批准上市

Repotrectinib

老挝国家药检所检测认证

非小细胞肺癌

Composition:

LUCIUS

Each Lucikepo capsule contains

Kepotrectinib ........
Indication:
osa nitase inhibitor indieated for the
eacht of adult patients with locallyadvance
carcer (NSCLC)

Dosage and Use:
Select patiemtef.

40mg

Poets lortee freatment of loc
K0Si rearrangement(s) intumor
specimens.

Repotrectinib Capsules

* Kecommended Dosage: 160 mg orally once
for 14davs. fhen inorasso tn 160

LuciRepo

FDA批准

with or without fosdg1ce dailv.

Capsules should be swallowed wbole & nut chewe
Storage: in a dry place and store at 20°C to 25°
Warning:
Keep medicine out of reach of Children. Do not

Rx onl

administer LuciRepo during Pregnancy and
Lactation.
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by
LUCIUS

60

权威认证

warning : To be sold by retail on prescription

Capsules

of registered physicians only, and as directed

口碑质量

适应症:

适用于治疗局部晚期或转移性ROS1-阳性非小细胞肺癌(NSCLC)的成年
患者。

推荐剂量:

每日口服一次,每次160mg(4粒),持续14天;然后增加到每日口服两次,
每次160mg(4粒),随餐或不随餐均可。